Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small cell lung cancer (NSCLC): Preliminary results. A study of the Swiss Group for Clinical Cancer Research (SAKK)

G. D’Addario(Kantonsspital St. Gallen), Daniel Betticher, J. Petersen(Kantonsspital St. Gallen), Miklos Pless(Ontario Institute for Cancer Research), Nicolas Mach(University of Geneva), Roger Stupp(Northwestern University), Kaspar Rufibach(Kantonsspital St. Gallen), R. Stahel, Daniel Rauch(Washington University in St. Louis)
Journal of Clinical Oncology
June 1, 2005
10.1200/jco.2005.23.16_suppl.7128
Cited by 5

Related Papers

<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
|New England Journal of Medicine|2005|7.2k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
|JAMA|2017|2.5k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k